|Last Update: 05/20/13 - 4:02 PM EDT|
|YTD Performance: 30.17%|
|Previous Close: $101.78|
|52 Week Range: $71.56 - $102.42|
|Oustanding Shares: 194,251,157|
|Market Cap: 19,770,882,759|
|Qtr (06/13)||Qtr (09/13)||FY (09/13)||FY (09/14)|
|Number of Analysts||13||12||16||13|
|Growth Rate (Year over Year)||-2.73%||7.34%||6.96%||9.04%|
Outperformance by safe sectors often signals trouble, but not always.
Portfolio Mgr. David Peltier uncovers a low-dollar healthcare stock with big growth potential.
This high-quality name seems ready for another sizable climb.
BDX was downgraded to Market Perform, Leerink Swann said. Valuation call, based on an $80 price target.
BDX was downgraded from Neutral to Underweight, JP Morgan said. $72 price target. Company is facing lower end-market demand.
Becton Dickinson’s P/E ratio is far below the 10-year median, and its payout has become quite generous.
At least three Fibonacci time cycles support a bullish stance against this recent low.
This surgical-products name has proven itself recession-resistant, and stands to make you money.
Traders awaited Greek debt-related news, testimony from Bernanke and some high-profile earnings reports.